Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

  • Wu Y
  • Zhou C
  • Hu C
 et al. 
  • 85


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Background: Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). We compared afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with EGFR mutation-positive advanced NSCLC. Methods: This open-label, randomised phase 3 trial was done at 36 centres in China, Thailand, and South Korea. After central testing for EGFR mutations, treatment-naive patients (stage IIIB or IV cancer [American Joint Committee on Cancer version 6], performance status 0-1) were randomly assigned (2:1) to receive either oral afatinib (40 mg per day) or intravenous gemcitabine 1000 mg/m2 on day 1 and day 8 plus cisplatin 75 mg/m2 on day 1 of a 3-week schedule for up to six cycles. Randomisation was done centrally with a random number-generating system and an interactive internet and voice-response system. Randomisation was stratified by EGFR mutation (Leu858Arg, exon 19 deletions, or other; block size three). Clinicians and patients were not masked to treatment assignment, but the independent central imaging review group were. Treatment continued until disease progression, intolerable toxic effects, or withdrawal of consent. The primary endpoint was progression-free survival assessed by independent central review (intention-to-treat population). This study is registered with, NCT01121393. Findings: 910 patients were screened and 364 were randomly assigned (242 to afatinib, 122 to gemcitabine and cisplatin). Median progression-free survival was significantly longer in the afatinib group (11·0 months, 95% CI 9·7-13·7) than in the gemcitabine and cisplatin group (5·6 months, 5·1-6·7; hazard ratio 0·28, 95% CI 0·20-0·39; p

Author-supplied keywords

  • Asian
  • China
  • Karnofsky Performance Status
  • NCT01121393
  • NCT01466660
  • South Korea
  • Thailand
  • abnormal laboratory result
  • acne
  • adult
  • advanced cancer
  • afatinib
  • aged
  • alopecia
  • anemia
  • arm pain
  • article
  • bone marrow depression
  • cancer staging
  • cisplatin
  • constipation
  • controlled study
  • coughing
  • diarrhea
  • disease course
  • drug dose escalation
  • drug dose reduction
  • drug efficacy
  • drug hypersensitivity
  • drug safety
  • dysphagia
  • dyspnea
  • epidermal growth factor receptor
  • epistaxis
  • fatigue
  • female
  • gemcitabine
  • gene deletion
  • gene mutation
  • hemoptysis
  • human
  • human tissue
  • hypokalemia
  • hyponatremia
  • insomnia
  • intention to treat analysis
  • leukopenia
  • loss of appetite
  • major clinical study
  • male
  • mouth pain
  • mucosa inflammation
  • multicenter study
  • multiple cycle treatment
  • nausea
  • neutropenia
  • non small cell lung cancer
  • open study
  • outcome assessment
  • pain
  • paronychia
  • peripheral neuropathy
  • phase 3 clinical trial
  • priority journal
  • progression free survival
  • pruritus
  • randomized controlled trial
  • rash
  • shoulder pain
  • stomatitis
  • survival time
  • thorax pain
  • thrombocytopenia
  • treatment duration
  • treatment response
  • vomiting
  • weakness

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Yi-Long Wu

  • Caicun Zhou

  • Cheng-Ping Hu

  • Jifeng Feng

  • Shun Lu

  • Yunchao Huang

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free